Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis

Li, Ting; Yu, Jiesen; Hou, Mengyuan; Zha, Sijie; Cheng, Qingqing; Zheng, Qingshan; Li, Lujin

doi:10.1016/j.phrs.2022.106592

Cited by 5 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parametric survival models were used to analyze OS and PFS data. The survival model is associated with a hazard function h(t), which can be interpreted as an instantaneous hazard function determined as follows [12,13] :…”

Section: Model Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. Methods A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3–4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. Results This study included 44 arms from 48 publications, with a total sample size of 7,881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and ORR of 40%. Whereas, PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and specific endocrine therapy used in combination significantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. Conclusion Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2- metastatic breast cancer in clinical guidelines.

show abstract

Section: Model Developmentmentioning

confidence: 99%

“…The Pearson correlation coe cient (R 2 ) was used to measure the strength of correlation among them. We considered a prespeci ed R 2 values of ≥ 0.8 to indicate a high correlation, 0.6-0.8 to indicate a moderate correlation, and < 0.6 to indicate a low correlation[12,15].…”

mentioning

confidence: 99%

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…However, some patients may not respond to these treatments or may experience a relapse following initial treatment with standardized chemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (3)(4)(5), leading to the development of relapsed/refractory DLBCL (r/r DLBCL). r/r DLBCL is a complex condition frequently associated with a poor prognosis (6,7). Although there are several treatment options available for patients with r/r DLBCL, such as R-CHOP, epigenetic therapy and targeted therapy, the therapeutic effects remain unsatisfactory (8).…”

Section: Introductionmentioning

confidence: 99%

Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B‑cell lymphoma: A case report

Zhang,

Xu,

Pan

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying characteristics, in terms of genomic variation, cell morphology and clinical presentation. At present, only ~66% of patients are cured with initial treatment and those with refractory DLBCL exhibit a poor prognosis. Thus, further investigations into novel effective treatment options for DLBCL are required. The present study reports the case of a patient resistant to multiple therapies, including rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus enzastaurin (trial no. CTR20171560), GemOx plus lenalidomide and selinexor (trial no. ATG-010-DLBCL-001). The patient harbored a CD274 amplification, as identified via next-generation sequencing (NGS), and exhibited a high programmed death-ligand 1 Tumor Proportion Score of up to 95%. Consequently, the patient was treated with sintilimab monotherapy and the response lasted for 12 months of follow-up without major immune-related adverse events. This case highlights the role of NGS technology in selecting treatment options for refractory DLBCL. Furthermore, the results of the present study suggest that sintilimab may have potential in the treatment of patients with refractory DLBCL.

show abstract

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The aim of this study was to quantitatively compare the e cacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2-metastatic breast cancer. MethodsA parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. ResultsThis study included 44 arms from 48 publications, with a total sample size of 7,881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and ORR of 40%. Whereas, PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and speci c endocrine therapy used in combination signi cantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. ConclusionOur study provides solid quantitative evidence for the rst-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2-metastatic breast cancer in clinical guidelines.

show abstract

Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis

Cited by 5 publications

References 49 publications

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B‑cell lymphoma: A case report

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer

Contact Info

Product

Resources

About